Celaid has raised 1.2 billion yen in its Series A financing round to advance HSC-based cell and gene therapies and platform

Celaid Therapeutics (Celaid), a Japan-based biotech developing Hematopoietic Stem Cell (HSC) therapies, today announced that it has raised an additional 460 million yen in its Series A extension round. This round was led by The University of Tokyo Edge Capital Partners (UTEC) and OSAKA University Venture Capital (OUVC) with participation from Techno Science and Joyo Capital Partners. This brings Celaid’s total raise to approximately 1.2 billion yen which includes existing Series A funding of 500 million yen and the recent 200 million yen from the NEDO Deep Tech Startup grant.

Cyto-Facto Inc. has raised 1.18 billion Yen through third-Party allocation shares as Series A.

Cyto-Facto has raised a total of 1.18 billion Yen through the third-party allocation of shares as Series A Fund-raising with investments from MPower Partners and D3 LLC as lead investors respectively, and many business corporations and VCs including Asahi Kasei, Mitsubishi Corporation, Kobe University Capital, Mizuho Capital, SMBC Venture Capital, and others as follower investors.